Troubled Biotechs: Orexigen, Telik, Trubion
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
You may also be interested in...
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.
Trubion Finds Kindred Spirit in Facet For Co-Development And Commercialization
Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.